As we say goodbye to 2023, Molecule to Market celebrates a year of impressive growth and an expanding listenership. Our podcast has had the privilege of collaborating with exceptional guests from the entire spectrum of the life sciences ecosystem.

Our episodes have covered a wide range of topics, exploring emerging trends and longstanding industry challenges. We have featured a mix of renowned industry leaders and captivating newcomers, making for engaging conversations.

These insightful discussions in 2023 have captivated our audience, leading to a significant increase in our listener base, nearly doubling in less than a year. What’s even more thrilling is our global reach. Our guests have attracted listeners from around the world, including the United States, United Kingdom, India, Germany, Canada, and Singapore.

Join us as we delve deeper into the world of life sciences and continue to bring you incredible conversations in the coming year.

Now, let’s take a look back at some of our favorite episodes from 2023

Barbara Morgan: Barbara’s journey into biopharma

Barbara shares her story of believing in herself and making brave decisions, including leaving a job she loved at a company that felt like family. She discusses the indispensability of Pharma while assuring listeners that the biopharma slowdown is just a temporary blip. 

Barbara also distinguishes between mentors and sponsors,  emphasizing the need for a blend of both. She imparts valuable lessons for mastering M&A assessment and integration to prioritize impact.

Mark Bamforth: Founding and selling three bio CDMOs (Part 1 & Part 2)

Discover Mark’s journey from oil barrels to brewing to a not-so-small biotech called Genzyme. He shares his experience of raising money for a self-funded CDMO carve-out after spending 22 years in the corporate world. 

Mark also discusses the merger strategy that led to the sale of Gallus BioPharmaceuticals to Patheon and the story of Brammer Bio’s start-up to a $1.7 billion exit to Thermo.

These episodes are not to be missed – no matter your role in life sciences, hear valuable life lessons from a man who’s seen it all. 

Ian Walters: Meet the lean, keen biotech

Ian talks about his time working with a team of Nobel Prize winners at Rockefeller University and how his lean biotech company breaks the mold – discover the process he underwent launching a clinical trial in just three months. 

He emphasizes the importance of building relationships with big pharma as a small biotech with multiple assets in the pipeline, all while conserving cash and building value.

Henal Shah: Think Star Trek, think Smart Labs

Henal decodes the concept of digital transformation and its impact on pharmaceutical companies throughout the life sciences supply chain. She offers fascinating insights into what a state-of-the-art smart factory and lab of the future might look like. 

She also discusses the complexity of collating siloed data and the importance of connecting, orchestrating, and presenting it in a meaningful way to aid decision-making. She highlights four key trends driving the pharmaceutical laboratories sector at present.

Tushar Misra: One-hour special: The biopharma outsourcer

Tushar shares his journey across roles, companies, and locations in the processing and biopharmaceutical sector. He discusses building a worldwide manufacturing and supply chain infrastructure for the commercial launch of a biologic oncology product globally for Takeda. 

He also delves into the key components of a strong CDMO partnership, the impact of different product types on the selection process, and the realities of a recent clinical failure for a biopharmaceutical company.

Matthew Stober: The problem-solving biopharma veteran

Matthew reveals how the failure of a big pharma R&D portfolio led to the creation of a CDMO business and a pipeline-ready facility. He shares leadership lessons for transitioning from a functional leader to an enterprise-level one and discusses his motivation to make a difference in the fight against cancer. 

Matthew also highlights the need for global harmonization and legislative changes in the industry.

Andi White: Microsoft talks to Molecule to Market

Andi discusses her experience at GE, which helped shape her into the leader she is today. She emphasizes the importance of having a broad mindset early in your career and explores the role of technology in revolutionizing the clinical trials and drug development space. 

She also shares her experience with AI technology and encourages listeners to think about how to maximize it for use with data, convenience, and research.

We can’t believe it’s been a whole year of providing you with valuable insights! But guess what? The journey doesn’t stop here.

Prepare for a roster of engaging episodes, inspiring guests, and game-changing knowledge. Molecule to Market is committed to celebrating and promoting the value and importance of the global life science outsourcing space.

Together, let’s make 2024 the year of growth, innovation, and endless possibilities in the life science industry. Stay tuned for what’s coming next!

Molecule to Market is sponsored by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed and grow in life sciences.